A Phase 2 Study of Vigil Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Nivolumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Gradalis
- 04 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 May 2017.
- 04 May 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 06 Jun 2016 Planned End Date changed from 1 Feb 2017 to 1 Sep 2017.